About Class E basic helix-loop-helix protein 40
Class E basic helix-loop-helix protein 40 (BHLHE40) is a protein
from Homo sapiens identified by UniProt accession
O14503, 412 residues long.
MolForge cross-references it against 0 known binders and
356 disease associations.
Target properties
| Protein name | Class E basic helix-loop-helix protein 40 |
| UniProt accession | O14503 |
| Gene | BHLHE40 |
| Organism | Homo sapiens |
| Length | 412 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (356)
Diseases linked to this target (Open Targets).
- Thyroid preparation use measurement · score 0.36
- hypothyroidism · score 0.36
- alkaline phosphatase measurement · score 0.36
- atopic eczema · score 0.29
- thyroid disease · score 0.28
- diabetes mellitus · score 0.28
- autoimmune thyroid disease · score 0.28
- endocrine system disease · score 0.28
- serum gamma-glutamyl transferase measurement · score 0.23
- Red cell distribution width · score 0.11
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O14503-F1 | alphafold | PREDICTED | 59.92 | — |
Amino-acid sequence (412 residues)
MERIPSAQPP PACLPKAPGL EHGDLPGMYP AHMYQVYKSR RGIKRSEDSK ETYKLPHRLI EKKRRDRINE CIAQLKDLLP EHLKLTTLGH LEKAVVLELT LKHVKALTNL IDQQQQKIIA LQSGLQAGEL SGRNVETGQE MFCSGFQTCA REVLQYLAKH ENTRDLKSSQ LVTHLHRVVS ELLQGGTSRK PSDPAPKVMD FKEKPSSPAK GSEGPGKNCV PVIQRTFAHS SGEQSGSDTD TDSGYGGESE KGDLRSEQPC FKSDHGRRFT MGERIGAIKQ ESEEPPTKKN RMQLSDDEGH FTSSDLISSP FLGPHPHQPP FCLPFYLIPP SATAYLPMLE KCWYPTSVPV LYPGLNASAA ALSSFMNPDK ISAPLLMPQR LPSPLPAHPS VDSSVLLQAL KPIPPLNLET KD
Explore Class E basic helix-loop-helix protein 40 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets